Antimicrobial Nanocoating

描述（由申请人提供）：医院（医院获得性）感染是医疗保健行业面临的最严重问题之一。在美国每年报告的约200万例医院获得性感染中，约有一半与导管、输尿管支架、中心静脉导管和其他经皮器械有关，这些器械为微生物追踪到更深的组织提供了支撑表面。一个典型的感染可能会花费高达47,000美元治疗每个病人。虽然侵入性医疗设备，如支架和导管是预先消毒，并插入或植入在最无菌条件下提供;生物膜生长，结壳，和随后的感染是最常见的失败模式。可以使这些装置固有地抵抗生物膜形成和结壳的涂层可以显著降低感染和不必要的疾病的发生率，允许更好地利用医疗保健资源，降低医疗保健成本，并挽救生命。结壳是由于器械表面的生物膜中掺入矿物质所致。这些沉积物抑制引流;是毒性细菌储库;并增加局部组织对感染的易感性。抗生素策略已被证明在预防支架和导管的生物膜形成和结壳方面价值不大。一种用于生产抗微生物表面的技术是施加能够在暴露于湿气时释放金属离子的涂层。抗微生物银离子特别适用于体内使用，因为它们基本上不被吸收到体内。在第一阶段，Brighton Technologies Group开发并表征了一种基于含银盐聚合物的气相沉积的新型抗菌纳米涂层（AMNC），该聚合物可有效抑制多种微生物的生物膜形成。第二阶段将扩展这些结果，以创建一个抗菌表面，将抑制生物膜的形成和结壳的医疗器械，如支架和留置导管通过：1。开发用于在泌尿装置（例如输尿管支架、Foley导管和输尿管导管）上沉积这些膜的技术。2.评估重要的AMNC特性，如疏水性/亲水性、摩擦系数、附着力和耐磨性。3.开发AMNC的活性和有效寿命作为结构和组成的函数的预测知识。4.启动体内性能和生物相容性评价。在美国，每年报告约200万例医院获得性感染，其中9万例导致死亡。减少传染病在医疗机构和整个社区的传播，最终将转化为拯救生命、提高生产力和改善数百万人的生活质量。布莱顿科技集团的抗菌纳米涂层设计用于使医疗设备和手接触表面自我消毒，以消除一些最常见的感染传播渠道。

DESCRIPTION (provided by applicant): Nosocomial (hospital acquired) infections represent one of the most severe problems facing the health care industry. Of the approximately two million hospital acquired infections reported annually in this country, about half are associated with catheters, ureteral stents, central lines and other percutaneous devices that provide a support surface for organisms to track into deeper tissue. A typical infection can cost as much as $47,000 per patient to treat. Although invasive medical devices such as stents and catheters are pre-sterilized and inserted or implanted under the most sterile conditions available; biofilm growth, encrustation, and subsequent infection are the most common mode of failure. Coatings that could render these devices inherently resistant to biofilm formation and encrustation could significantly reduce the incidence of infections and unnecessary illness, allow better use of health care resources, reduce healthcare costs, and save lives. Encrustation results from mineral incorporation into biofilms on device surfaces. These deposits inhibit drainage; are virulent bacterial reservoirs; and increase susceptibility of the local tissues to infection. Antibiotic strategies have proven to be of little value in preventing biofilm formation and encrustation of stents and catheters. One technique for producing antimicrobial surfaces is to apply a coating which is capable of releasing metal ions when exposed to moisture. Antimicrobial silver ions are particularly useful for in vivo use due to the fact that they are not substantially absorbed into the body. In Phase I, Brighton Technologies Group developed and characterized a novel antimicrobial nanocoating (AMNC) based on gas-phase deposition of a silver salt-containing polymer that effectively inhibits biofilm formation for a wide range of microorganisms. Phase II will extend these results to create an antimicrobial surface that will inhibit biofilm formation and encrustation on medical devices such as stents and indwelling catheters through: 1. Developing techniques for depositing these films on urinary devices such as ureteral stents, Foley catheters, and ureteral catheters. 2. Evaluating important AMNC characteristics such as hydrophobicity/hydrophilicity, coefficient of friction, adhesion and wear resistance. 3. Developing predictive knowledge of activity and effective lifetime of AMNC's as a function of structure and composition. 4. Initiating in vivo performance and biocompatibility evaluations. Approximately two million hospital-acquired infections are reported annually in the USA, 90,000 of which result in death. Reducing the spread of infectious diseases within healthcare facilities, and in the general community would ultimately translate to saving lives, increasing productivity, and improving the quality of life for millions. Brighton Technologies Group, Inc.'s Antimicrobial Nanocoating is designed to render medical device and hand-contact surfaces self-sterilizing to eliminate some the most common conduits for infection transmission.